CRVS
Corvus Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 68 | +6 | 34.72M | $518.70M | +11 | −5 |
| Q1 2026 | 64 | +8 | 30.80M | $450.00M | +15 | −7 |
| Q4 2025 | 56 | +2 | 25.04M | $192.77M | +2 | n/a |
| Q3 2025 | 14 | 0 | 18.71M | $137.91M | +2 | −2 |
| Q2 2025 | 11 | -1 | 17.31M | $69.23M | +1 | −2 |
| Q1 2025 | 9 | +2 | 6.14M | $19.53M | +2 | n/a |
| Q4 2024 | 7 | -1 | 4.46M | $23.85M | n/a | −1 |
| Q3 2024 | 7 | 0 | 7.32M | $38.63M | n/a | n/a |
| Q2 2024 | 7 | n/a | 7.37M | $13.41M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management ✦ | 5.96M | n/a | $10.86M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 563.93K | n/a | $1.03M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 460.14K | n/a | $837,619 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 204.60K | n/a | $372,368 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Marshall Wace ✦ | 74.56K | n/a | $135,698 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 53.01K | n/a | $96,478 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 7 | Two Sigma Investments ✦ | 47.79K | n/a | $86,971 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 163 holders, 69.83M shares, $976.09M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.